多面策略,提高学生在先进药房实践经验中获得可信任的专业活动的成就
Jane Shtaynberg1, Anastasia Rivkin1, Lillian Rozaklis1
1Fairleigh Dickinson University School of Pharmacy & Health Sciences, Florham Park, NJ, USA.
这项研究实施了纵向监测和个性化干预措施,以帮助药学学生实现可信任的专业活动 (EPAs) 委托. 这种方法成功地确保所有学生都符合EPA要求,防止毕业延迟.
科学领域:
- 药房 教育 教育 药房 教育
- 基于能力的教育 基于能力的教育
- 专业发展专业发展
背景情况:
- 传统的药学教育依赖于总结性评估.
- 获得可信任的专业活动 (EPA) 对药学毕业生至关重要.
- 早期识别和干预是学生在高级药房实践经验 (APPE) 中取得成功的关键.
研究的目的:
- 描述一种新的方法,以加强对APPE的EPA信任.
- 为处于危险的学生实施纵向监测和个性化干预措施.
- 尽量减少对年底补救的需要,并确保及时毕业.
主要方法:
- 使用了核心APPE (急症护理,门诊护理,社区,机构) 与定义的EPA.
- 实施了一个"EPA报告卡",用于连续的纵向监测.
- 雇佣个人化,在序列干预 (主动推广,补救) 确定为有风险的学生.
主要成果:
- 12-16%的学生被确定为不符合EPA委托的风险.
- 所有被识别的学生在完成APPE时都获得了"3级"的委托 (执行反应式监督).
- 没有学生需要为EPA缺陷进行年终补救,确保毕业.
结论:
- 一个多方面的战略有效地支持了EPA对APPE的信任.
- 纵向监测和及时干预可以提高学生的成绩.
- 这种方法减少了补救需求,并防止了毕业延迟.
更多相关视频
05:04Author Spotlight: Evaluating Clinicians' Adoption of Ultrasound-Guided Vascular Cannulation Through Simulation Training
Published on: August 9, 2024
07:32Preparation and Characterization of Individual and Multi-drug Loaded Physically Entrapped Polymeric Micelles
Published on: August 28, 2015
相关概念视频
Nursing Process for Patient and Caregiver Teaching II: Planning and Implementation
Guidelines for Writing Outcome
Patient outcomes reflect the patient's response to the goal rather than what the nurse aims to achieve. Terminology should be observable and measurable to avoid the reader's interpretation. The desired outcome should be realistic and achievable in the designated care timeframe. Expected outcomes should align with adjunctive therapies. The outcome should enhance care...
The Professional Nurse
Communication skills: These are critical characteristics, especially speaking and listening.
Fundamentals of Nursing Process II
Drug Administration and Therapy Phases: Overview
The pharmaceutical phase focuses on leveraging the physicochemical properties of the drug to design and manufacture an effective product. Variants include orally administered tablets or capsules, topical creams or ointments, and parenteral-delivery solutions or emulsions.
The pharmacokinetic phase...
Ethical Dilemmas II
